Brokering the boundary between science and advocacy: the case of intermittent preventive treatment among infants

Health Policy and Planning

Volumn 28, Issue 6, 2013, Pages 616-625

  Cruz, Valeria Oliveira ^a   Walt, Gill ^a  

^a LONDON SCHOOL OF HYGIENE AND TROPICAL MEDICINE   (United Kingdom)

Author keywords

ideas; institutions; interests; knowledge translation; research advocacy policy interface

Indexed keywords

ARTICLE; CONFLICT; HEALTH CARE PLANNING; HUMAN; IDEAS; INFANT; INSTITUTIONS; INTERESTS; KNOWLEDGE TRANSLATION; MALARIA; ORGANIZATION AND MANAGEMENT; PATIENT ADVOCACY; PRIMARY PREVENTION; RESEARCH-ADVOCACY-POLICY INTERFACE; TRANSLATIONAL RESEARCH;

IDEAS; INSTITUTIONS; INTERESTS; KNOWLEDGE TRANSLATION; RESEARCH-ADVOCACY-POLICY INTERFACE;

CONFLICT (PSYCHOLOGY); EFFICIENCY, ORGANIZATIONAL; HEALTH PLAN IMPLEMENTATION; HUMANS; INFANT; MALARIA; PATIENT ADVOCACY; PRIMARY PREVENTION; TRANSLATIONAL MEDICAL RESEARCH;

EID: 84883486173     PISSN: 02681080     EISSN: 14602237     Source Type: Journal    
DOI: 10.1093/heapol/czs101     Document Type: Article

References (63)

1. Alonso PL, Lindsay SW, Armstrong JR et al. 1991. The effect of insecticide-treated bed nets on mortality of Gambian children. The Lancet 337: 1499-502.
2. Aponte JJ, Shellenberg D, Egan A et al. 2009. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: A pooled analysis of six randomised, placebo-controlled trials. The Lancet 374: 1533-42.
3. Black N. 2001. Evidence based policy: Proceed with care. British Medical Journal 323: 275-9.
4. Black RE, Bhan MK, Chopra M et al. 2009. Accelerating the health impact of the Gates Foundation. The Lancet 373: 1584-85.
5. Bradley D. 1999. The last and the next hundred years of malariology. Parassitologia 41: 11-8.
6. Buekens P, Keusch G, Belizan J, Bhutta ZA. 2004. Evidence-based global health. Editorial. JAMA 291: 2639-41.
7. Buse K. 2008. Addressing the theoretical, practical and ethical challenges inherent in prospective health policy analysis. Health Policy and Planning 23: 351-60.
8. Buse K, Mays N, Walt G. 2012. Making Health Policy. 2nd edn. Berkshire: Open University Press.
9. Chandramohan D, Owusu-Agyei S, Carneiro I et al. 2005. Cluster randomised trial of intermittent preventive treatment for malaria in infants in area of high, seasonal transmission in Ghana. BMJ 331: 727-33.
10. Cliff J, Lewin S, Woelk G et al. 2010. Policy development in malaria vector management in Mozambique, South Africa and Zimbabwe. Health Policy and Planning 25: 372-83.
11. Conteh L, Sicuri E, Manzi F et al. 2010. The cost-effectiveness of intermittent preventive treatment for malaria in infants in Sub-Saharan Africa. PLoS One 5: E10313.
12. Cook DM, Boyd EA, Grossmann C, Bero LA. 2007. Reporting science and conflicts of interest in the lay press. PLoS One 2: E1266.
13. Davis P, Howden-Chapman P. 1996. Translating research findings into health policy. Social Science and Medicine 43: 865-72.
14. Frenk J. 2008. Strengthening Health Systems: Towards New Forms of Global Cooperation. Paper presented at Meeting on Global Health and the United Nations, Carter Center, Atlanta, GA, USA.
15. Global Fund. 2009. Grant Portfolio, Malaria Component. http://www.theglobalfund.org/programs/search/?lang-en&component- Malaria, accessed 26 September 2009.
16. Gosling RD, Gesase S, Mosha JF et al. 2009. Protective efficacy and safety of three antimalarial regimens for intermittent preventive treatment for malaria in infants: A randomised, placebo-controlled trial. Lancet 374: 1521-32.
17. Grobusch MP, Lell B, Schwarz NG et al. 2007. Intermittent preventive treatment against malaria in infants in Gabon-a randomized, double-blind, placebo-controlled trial. Journal of Infectious Disease 196: 1595-1602.
18. Howlett M, Ramesh M, Perl A. 2009. Studying Public Policy. Oxford: Oxford University Press. In stitute of Medicine. 2008. Assessment of the Role of Intermittent Preventive Treatment for Malaria in Infants: Letter Report. Washington, DC: The National Academies Press.
19. IPTi Consortium. 2003. Intermittent preventive treatment with antimalarial drugs delivered through the Expanded Programme of Immunisation: A new potential public health strategy to reduce the burden of malaria in young African children. A proposal to the Bill and Melinda Gates Foundation from the IPTi Consortium, 18 April.
20. IPTi Consortium. 2009. Letter to the Co-Chairs of the WHO Technical Expert Group, 28 May 2009.
21. Kobbe R, Kreuzberg C, Adjei S et al. 2007. A randomized controlled trial of extended intermittent preventive antimalarial treatment in infants. Clinical Infectious Disease 45: 16-25.
22. Lancet. 2007. Correspondence. The Lancet 370: 824-27.
23. Lancet. 2009. What has the Gates Foundation done for global health?. The Lancet 373: 1577.
24. Lavis JN. 2006. Research, public policymaking, and knowledgetranslation processes: Canadian efforts to build bridges. Journal of Continuing Education in Health Professions 26: 37-45.
25. Lengeler C. 2004. Insecticide-treated bed nets and curtains for preventing malaria. Cochrane Database Syst Rev CD000363.
26. Macete E, Aide P, Aponte JJ et al. 2006. Intermittent preventive treatment for malaria control administered at the time of routine vaccinations in Mozambican infants: A randomized, placebocontrolled trial. Journal of Infectious Disease 194: 276-85.
27. Mamudu H, Gonzalez ME, Glantz S. 2011. The nature, scope, and development of the global Tobacco Control epistemic community. American Journal of Public Health 101: 2044-54.
28. Massaga JJ, Kitua AY, Lemnge MM et al. 2003. Effect of intermittent treatment with amodiaquine on anaemia and malarial fevers in infants in Tanzania: A randomised placebo controlled trial. The Lancet 361: 1853-60.
29. Mockenhaupt FP, Reither K, Zanger P et al. 2007. Intermittent preventive treatment in infants as a means of malaria control: A randomized, double-blind, placebo-controlled trial in northern Ghana. Antimicrobial Agents and Chemotherapy 51: 3273-81.
30. Moher D, Cook DJ, Eastwood S, Olkin I, Rennie D, Stroup for the QUOROM Group DF. 1999. Improving the quality of reports of meta-analyses of randomised controlled trials: The QUOROM statement. The Lancet 354: 1896-1900.
31. North D. 1989. Institutions and economic growth: A historical introduction. World Development 17: 1319-32.
32. Odhiambo FO, Hamel MJ, Williamson J et al. 2010. Intermittent preventive treatment in infants for the prevention of malaria in rural Western Kenya: A randomized, double-blind placebocontrolled trial. PLoS One 5: E10016.
33. Oliveira-Cruz V, Walt G. 2009. Translating research into policy: The case of Intermittent Preventive Treatment in Infants (IPTi). Study report. London: London School of Hygiene and Tropical Medicine.
34. Oxman AD, Lavis JN, Fretheim A. 2007. Use of evidence in WHO recommendations. Lancet 369: 1883-89.
35. Oxman AD, Lavis JN, Lewin S, Fretheim A. 2009. SUPPORT Tools for evidence-informed health policymaking (STP) 1: What is evidenceinformed policymaking?. Health Research Policy and Systems 7(Suppl. 1):S1.
36. Parise ME, Ayisi JG, Nahlen BL et al. 1998. Efficacy of sulfadoxinepyrimethamine for prevention of placental malaria in an area of Kenya with a high prevalence of malaria and human immunodeficiency virus infection. American Journal of Tropical Medicine and Hygiene 59: 813-22.
37. Sabatier P (ed). 2007. Theories of the Policy Process. Westview Press: University of California.
38. Schellenberg D, Menendez C, Kahigwa E et al. 2001. Intermittent treatment for malaria and anaemia control at time of routine vaccinations in Tanzanian infants: A randomised, placebo-controlled trial. Lancet 357: 1471-77.
39. Schellenberg JR, Maokola W, Shirima K et al. 2011. Cluster-randomized study of intermittent preventive treatment for malaria in infants (IPTi) in southern Tanzania: Evaluation of impact on survival. Malaria Journal 10: 387.
40. Shearer JC, Stack ML, Richmond MR et al. 2010. Accelerating policy decisions to adopt Haemophilus influenza Type b Vaccine: A global, multivariable analysis. PLoS Medicine 7: E1000249.
41. Shiffman J, Smith S. 2007. Generation of political priority for global health initiatives: A framework and case study of maternal mortality. The Lancet 370: 1370-9.
42. Shretta R, Omumbo J, Rapuoda B, Snow RW. 2000. Using evidence to change antimalarial drug policy in Kenya. Tropical Medicine and International Health 5: 775-64.
43. Shulman CE, Dorman EK, Cutts F et al. 1999. Intermittent sulphadoxinepyrimethamine to prevent severe anaemia secondary to malaria in pregnancy: A randomised placebo-controlled trial. Lancet 353: 632-36.
44. Stuckler D, Basu S, McKee M. 2011. Global Health Philanthropy and Institutional Relationships: How should conflicts of interest be addressed?. PLoS Medicine 8: E1001020.
45. Sufrin C, Ross JS. 2008. Pharmaceutical industry marketing: Understanding its impact on women's health. Obstetrical and Gynecological Survey 63: 585-96.
46. Sumner A, Crichton J, Theobald S, Zulu E, Parkhurst J. 2011. What shapes research impact on policy?. Understanding research uptake in sexual and reproductive health policy processes in resource poor contexts. Health Research Policy and Systems 9(Suppl. 1):S3.
47. The PLoS Medicine Editors. 2008. Making sense of non-financial competing interests. PLoS Medicine 5: E199.
48. Walt G. 1994. How far does research influence policy?. European Journal of Public Health 4: 233-5.
49. Walt G, Gilson L. 1994. Reforming the health sector in developing countries: The central role of policy analysis. Health Policy and Planning 9: 353-70.
50. Weiss CH. 1979. The many meanings of research utilization. Public Administration Review 39: 426-31.
51. WHO. 2000. WHO Expert Committee on Malaria. Technical Report Series, Vol. 892. Geneva: WHO.
52. WHO. 2003. Position of WHO's Roll Back Malaria Department on malaria treatment policy. http://www.emro.who.int/RBM/WHOPositionsStatement.pdf, accessed 2 July 2009.
53. WHO. 2006. Planning for success. A WHO policy platform for Intermittent Preventive Treatment in Infants (IPTi). A proposal to the Bill and Melinda Gates Foundation on behalf of the IPTi Consortium. February 2006.
54. WHO. 2008. World Malaria Report. http://apps.who.int/malaria/wmr2008/ malaria2008.pdf, accessed 26 September 2009.
55. WHO. 2010. WHO policy recommendation on Intermittent Preventive Treatment during infancy with sulphadoxinepyrimethamine (SP-IPTi) for Plasmodium falciparum malaria control in Africa.
56. WHO. 2010. World Malaria Report. http://www.who.int/malaria/world- malaria-report-2010/en/index.html, accessed 5 October 2011.
57. WHO TEG. 2006. Report of the technical consultation on Intermittent Preventive Therapy in Infancy (IPTi), WHO Technical Expert Group.
58. WHO TEG. 2007. Report of the Technical Expert Group (TEG) meeting on Intermittent Preventive Therapy in Infancy (IPTi). Geneva, 8-10 October 2007.
59. WHO TEG. 2009. Report of the Technical Consultation on Intermittent Preventive Treatment in Infants (IPTi). Technical Expert Group meeting on preventive chemotherapy. Geneva: WHO headquarters, 23-24 April 2009.
60. WHO [Global Malaria Programme (GMP) and Department of Immunization, Vaccines & Biologicals (IVB)] and UNICEF. 2011.
61. On Intermittent Preventive Treatment for infants with sulphadoxi ne-pyrimethamine (SP-IPTi) for malaria control in Africa: Implementation Field Guide. Geneva: WHO/IVB/11.07.
62. Williams HA, Durrheim D, Shretta R. 2004. The process of changing national malaria treatment policy: Lessons from country level studies. Health Policy and Planning 19: 356-70.
63. Woelk G, Daniels K, Cliff J et al. 2009. Translating research into policy: Lessons learned from eclampsia treatment and malaria control in three southern African countries. Health Research Policy and Systems. 7: 31.